Work

Performance Dependent Parameters of a Liposome Formulation of a Hydrophobic Drug

Year: 2018
Type: dissertation
Abstract: MLN-4924 is a newly discovered potent compound that works on the ubiquitin pathway and is currently being evaluated in Phase I, II, III clinical trials for treatment of a variety of malignancies. This compound has also shown potential preclinical value for the treatment of retinoblastoma, a malignant tumor that usually originates in the retina in young children. However, its limited aqueous solubility prevents reproducible intravitreal administration at therapeutic doses for the treatment of retinoblastoma. In previous studies, the poor stability of MLN-4924 was addressed by use of DMSO, cyclodextrin and dextrose. However, these studies could only improve the solubility of MLN-4924 by a modest amount and resulted in formulations with a limited payload, burst release profile or poor stability. In this research, we designed a stable liposome formulation of MLN-4924 that encapsulates a higher therapeutic payload of this drug and has physicochemical characteristics that make it amenable to intravitreal administration.
Author: Xinpei Li
Language: English
Open Access status: green
OpenAlex ID: W2944942520
Cites: 111
Cited by:
Related to: 10